AMGN vs GILD vs BIIB

For growth investors, Amgen Inc.

(AMGN) is the stronger pick with 9. 9% revenue growth year-over-year, versus 1. 4% for Biogen Inc. (BIIB). Biogen Inc. (BIIB) offers the better valuation at 21. 6x trailing P/E (13. 0x forward), making it the more compelling value choice. Analysts rate Amgen Inc. (AMGN) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Biogen Inc.

(BIIB) is the cheapest at 21. 6x versus Gilead Sciences, Inc. at 358. 7x. On forward P/E, Biogen Inc. is actually cheaper at 13. 0x.

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +127. 5%, compared to -29. 9% for Biogen Inc. (BIIB). Over 10 years, the gap is even starker: AMGN returned +161. 5% versus BIIB's -27. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amgen Inc.

(AMGN) is the lower-risk stock at 0. 60β versus Gilead Sciences, Inc. 's 0. 66β — meaning GILD is approximately 9% more volatile than AMGN relative to the S&P 500. On balance sheet safety, Biogen Inc. (BIIB) carries a lower debt/equity ratio of 38% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Amgen Inc.

(AMGN) is pulling ahead at 9. 9% versus 1. 4% for Biogen Inc. (BIIB). On earnings-per-share growth, the picture is similar: Amgen Inc. grew EPS 88. 2% year-over-year, compared to -91. 6% for Gilead Sciences, Inc.. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amgen Inc.

(AMGN) is the more profitable company, earning 21. 0% net margin versus 1. 7% for Gilead Sciences, Inc. — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMGN leads at 29. 1% versus 5. 8% for GILD. At the gross margin level — before operating expenses — GILD leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Biogen Inc.

(BIIB) trades at 13. 0x forward P/E versus 15. 9x for Gilead Sciences, Inc. — 3. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GILD: 18. 8% to $161. 88.

In this comparison, AMGN (2.

9% yield), GILD (2. 3% yield) pay a dividend. BIIB does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Amgen Inc.

(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 60), 2. 9% yield, +161. 5% 10Y return). Both have compounded well over 10 years (AMGN: +161. 5%, BIIB: -27. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

AMGN, GILD pay a dividend while BIIB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.